Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis

Joseph L. Jorizzo, Frank C. Schmalstieg, Alvin Jr Solomon, Tito Cavallo, Robert S. Taylor, Helen B. Rudloff, Elisabeth J. Schmalstieg, Jerry C. Daniels

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

• Pustular vasculitis is a new disease concept that links cutaneous, and possibly systemic, aspects of Behçet’s, bowel bypass, bowel-associated dermatosis-arthritis, and disseminated gonorrhea syndromes. The pathomechanism of pustular vasculitic lesion generation may relate to circulating immune complex (CIC)-mediated vessel damage and serum enhancement of neutrophil migration. Thalidomide, an oral pharmaceutical available on strict protocol, has therapeutic effects based on proposed modulation of CIC- and neutrophil-mediated cytotoxicity. Thalidomide therapy was started for four patients with significant morbidity from Behçet’s syndrome and for one patient with bowel-associated dermatosis-arthritis syndrome. Clinical benefit was dramatic in all patients who completed sequential four-week “on” and “off” thalidomide therapeutic cycles. In three of four patients, in vivo testing for CIC after histamine injection immunopathology converted from positive (immunoreactant deposition in dermal vasculature [four hours after histamine] and CIC-mediated vasculitis [24 hours after histamine]) to negative during therapy. No effects were noted on neutrophil migration or on the LFA-1/Mac-1/p150,95 family of glycoproteins associated with neutrophil adherence as assessed qualitatively by tritium labeling of neutrophil cell surfaces. In this small patient group, thalidomide was a clinically effective, safe (with rigid monitoring) therapy whose mechanism of action may relate more to inhibitory effects on CIC-induced vasculitis than to effects on neutrophil-mediated cytotoxicity.

Original languageEnglish (US)
Pages (from-to)878-881
Number of pages4
JournalArchives of Internal Medicine
Volume146
Issue number5
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Thalidomide
Vasculitis
Antigen-Antibody Complex
Neutrophils
Histamine
Skin Diseases
Integrin alphaXbeta2
Arthritis
Lymphocyte Function-Associated Antigen-1
Skin
Tritium
Gonorrhea
Therapeutic Uses
Therapeutics
Morbidity
Injections
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Jorizzo, J. L., Schmalstieg, F. C., Solomon, A. J., Cavallo, T., Taylor, R. S., Rudloff, H. B., ... Daniels, J. C. (1986). Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis. Archives of Internal Medicine, 146(5), 878-881. https://doi.org/10.1001/archinte.1986.00360170074012

Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis. / Jorizzo, Joseph L.; Schmalstieg, Frank C.; Solomon, Alvin Jr; Cavallo, Tito; Taylor, Robert S.; Rudloff, Helen B.; Schmalstieg, Elisabeth J.; Daniels, Jerry C.

In: Archives of Internal Medicine, Vol. 146, No. 5, 1986, p. 878-881.

Research output: Contribution to journalArticle

Jorizzo, JL, Schmalstieg, FC, Solomon, AJ, Cavallo, T, Taylor, RS, Rudloff, HB, Schmalstieg, EJ & Daniels, JC 1986, 'Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis', Archives of Internal Medicine, vol. 146, no. 5, pp. 878-881. https://doi.org/10.1001/archinte.1986.00360170074012
Jorizzo JL, Schmalstieg FC, Solomon AJ, Cavallo T, Taylor RS, Rudloff HB et al. Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis. Archives of Internal Medicine. 1986;146(5):878-881. https://doi.org/10.1001/archinte.1986.00360170074012
Jorizzo, Joseph L. ; Schmalstieg, Frank C. ; Solomon, Alvin Jr ; Cavallo, Tito ; Taylor, Robert S. ; Rudloff, Helen B. ; Schmalstieg, Elisabeth J. ; Daniels, Jerry C. / Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis. In: Archives of Internal Medicine. 1986 ; Vol. 146, No. 5. pp. 878-881.
@article{12b378ce8da74b8390328720f2d6891d,
title = "Thalidomide Effects in Beh{\cc}et’s Syndrome and Pustular Vasculitis",
abstract = "• Pustular vasculitis is a new disease concept that links cutaneous, and possibly systemic, aspects of Beh{\cc}et’s, bowel bypass, bowel-associated dermatosis-arthritis, and disseminated gonorrhea syndromes. The pathomechanism of pustular vasculitic lesion generation may relate to circulating immune complex (CIC)-mediated vessel damage and serum enhancement of neutrophil migration. Thalidomide, an oral pharmaceutical available on strict protocol, has therapeutic effects based on proposed modulation of CIC- and neutrophil-mediated cytotoxicity. Thalidomide therapy was started for four patients with significant morbidity from Beh{\cc}et’s syndrome and for one patient with bowel-associated dermatosis-arthritis syndrome. Clinical benefit was dramatic in all patients who completed sequential four-week “on” and “off” thalidomide therapeutic cycles. In three of four patients, in vivo testing for CIC after histamine injection immunopathology converted from positive (immunoreactant deposition in dermal vasculature [four hours after histamine] and CIC-mediated vasculitis [24 hours after histamine]) to negative during therapy. No effects were noted on neutrophil migration or on the LFA-1/Mac-1/p150,95 family of glycoproteins associated with neutrophil adherence as assessed qualitatively by tritium labeling of neutrophil cell surfaces. In this small patient group, thalidomide was a clinically effective, safe (with rigid monitoring) therapy whose mechanism of action may relate more to inhibitory effects on CIC-induced vasculitis than to effects on neutrophil-mediated cytotoxicity.",
author = "Jorizzo, {Joseph L.} and Schmalstieg, {Frank C.} and Solomon, {Alvin Jr} and Tito Cavallo and Taylor, {Robert S.} and Rudloff, {Helen B.} and Schmalstieg, {Elisabeth J.} and Daniels, {Jerry C.}",
year = "1986",
doi = "10.1001/archinte.1986.00360170074012",
language = "English (US)",
volume = "146",
pages = "878--881",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Thalidomide Effects in Behçet’s Syndrome and Pustular Vasculitis

AU - Jorizzo, Joseph L.

AU - Schmalstieg, Frank C.

AU - Solomon, Alvin Jr

AU - Cavallo, Tito

AU - Taylor, Robert S.

AU - Rudloff, Helen B.

AU - Schmalstieg, Elisabeth J.

AU - Daniels, Jerry C.

PY - 1986

Y1 - 1986

N2 - • Pustular vasculitis is a new disease concept that links cutaneous, and possibly systemic, aspects of Behçet’s, bowel bypass, bowel-associated dermatosis-arthritis, and disseminated gonorrhea syndromes. The pathomechanism of pustular vasculitic lesion generation may relate to circulating immune complex (CIC)-mediated vessel damage and serum enhancement of neutrophil migration. Thalidomide, an oral pharmaceutical available on strict protocol, has therapeutic effects based on proposed modulation of CIC- and neutrophil-mediated cytotoxicity. Thalidomide therapy was started for four patients with significant morbidity from Behçet’s syndrome and for one patient with bowel-associated dermatosis-arthritis syndrome. Clinical benefit was dramatic in all patients who completed sequential four-week “on” and “off” thalidomide therapeutic cycles. In three of four patients, in vivo testing for CIC after histamine injection immunopathology converted from positive (immunoreactant deposition in dermal vasculature [four hours after histamine] and CIC-mediated vasculitis [24 hours after histamine]) to negative during therapy. No effects were noted on neutrophil migration or on the LFA-1/Mac-1/p150,95 family of glycoproteins associated with neutrophil adherence as assessed qualitatively by tritium labeling of neutrophil cell surfaces. In this small patient group, thalidomide was a clinically effective, safe (with rigid monitoring) therapy whose mechanism of action may relate more to inhibitory effects on CIC-induced vasculitis than to effects on neutrophil-mediated cytotoxicity.

AB - • Pustular vasculitis is a new disease concept that links cutaneous, and possibly systemic, aspects of Behçet’s, bowel bypass, bowel-associated dermatosis-arthritis, and disseminated gonorrhea syndromes. The pathomechanism of pustular vasculitic lesion generation may relate to circulating immune complex (CIC)-mediated vessel damage and serum enhancement of neutrophil migration. Thalidomide, an oral pharmaceutical available on strict protocol, has therapeutic effects based on proposed modulation of CIC- and neutrophil-mediated cytotoxicity. Thalidomide therapy was started for four patients with significant morbidity from Behçet’s syndrome and for one patient with bowel-associated dermatosis-arthritis syndrome. Clinical benefit was dramatic in all patients who completed sequential four-week “on” and “off” thalidomide therapeutic cycles. In three of four patients, in vivo testing for CIC after histamine injection immunopathology converted from positive (immunoreactant deposition in dermal vasculature [four hours after histamine] and CIC-mediated vasculitis [24 hours after histamine]) to negative during therapy. No effects were noted on neutrophil migration or on the LFA-1/Mac-1/p150,95 family of glycoproteins associated with neutrophil adherence as assessed qualitatively by tritium labeling of neutrophil cell surfaces. In this small patient group, thalidomide was a clinically effective, safe (with rigid monitoring) therapy whose mechanism of action may relate more to inhibitory effects on CIC-induced vasculitis than to effects on neutrophil-mediated cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0022559816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022559816&partnerID=8YFLogxK

U2 - 10.1001/archinte.1986.00360170074012

DO - 10.1001/archinte.1986.00360170074012

M3 - Article

C2 - 3963978

AN - SCOPUS:0022559816

VL - 146

SP - 878

EP - 881

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -